BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baci D, Bosi A, Gallazzi M, Rizzi M, Noonan DM, Poggi A, Bruno A, Mortara L. The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors. Int J Mol Sci 2020;21:E3125. [PMID: 32354198 DOI: 10.3390/ijms21093125] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Senent Y, Ajona D, González-Martín A, Pio R, Tavira B. The Complement System in Ovarian Cancer: An Underexplored Old Path. Cancers (Basel) 2021;13:3806. [PMID: 34359708 DOI: 10.3390/cancers13153806] [Reference Citation Analysis]
2 Yu L, Ding Y, Wan T, Deng T, Huang H, Liu J. Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer. Front Immunol 2021;12:768115. [PMID: 34966389 DOI: 10.3389/fimmu.2021.768115] [Reference Citation Analysis]
3 Ahn HS, Ho JY, Yu J, Yeom J, Lee S, Hur SY, Jung Y, Kim K, Choi YJ. Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers. Cancers (Basel) 2021;13:2300. [PMID: 34064977 DOI: 10.3390/cancers13102300] [Reference Citation Analysis]
4 Esmail S, Danter WR. Stem-cell based, machine learning approach for optimizing natural killer cell-based personalized immunotherapy for high-grade ovarian cancer. FEBS J 2021. [PMID: 34582617 DOI: 10.1111/febs.16214] [Reference Citation Analysis]
5 Monavarian M, Elhaw A, Tang P, Javed Z, Shonibare Z, Scalise CB, Arend R, Jolly MK, Sewell- Loftin MK, Hempel N, Mythreye K. Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.03.004] [Reference Citation Analysis]
6 Jin Y, Lin Q, Fei H, Xue L, Li L, Xi Q, Jiang H. Bioinformatics Analysis of Potential Therapeutic Targets and Prognostic Biomarkers amid CXC Chemokines in Ovarian Carcinoma Microenvironment. J Oncol 2021;2021:8859554. [PMID: 33763130 DOI: 10.1155/2021/8859554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Johnson RL, Cummings M, Thangavelu A, Theophilou G, de Jong D, Orsi NM. Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment. Cancers (Basel) 2021;13:6231. [PMID: 34944851 DOI: 10.3390/cancers13246231] [Reference Citation Analysis]
8 Xia L, Zhang H, Wang X, Zhang X, Nie K. The Role of Succinic Acid Metabolism in Ovarian Cancer. Front Oncol 2021;11:769196. [PMID: 34796116 DOI: 10.3389/fonc.2021.769196] [Reference Citation Analysis]
9 Cummings M, Freer C, Orsi NM. Targeting the tumour microenvironment in platinum-resistant ovarian cancer. Semin Cancer Biol 2021:S1044-579X(21)00030-4. [PMID: 33607246 DOI: 10.1016/j.semcancer.2021.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liang ZQ, Gao L, Chen JH, Dai WB, Su YS, Chen G. Downregulation of the Coiled-Coil Domain Containing 80 and Its Perspective Mechanisms in Ovarian Carcinoma: A Comprehensive Study. Int J Genomics 2021;2021:3752871. [PMID: 34820451 DOI: 10.1155/2021/3752871] [Reference Citation Analysis]
11 Li XX, Xiong L, Wen Y, Zhang ZJ. Comprehensive Analysis of the Tumor Microenvironment and Ferroptosis-Related Genes Predict Prognosis with Ovarian Cancer. Front Genet 2021;12:774400. [PMID: 34868262 DOI: 10.3389/fgene.2021.774400] [Reference Citation Analysis]
12 Luo X, Xu J, Yu J, Yi P. Shaping Immune Responses in the Tumor Microenvironment of Ovarian Cancer. Front Immunol 2021;12:692360. [PMID: 34248988 DOI: 10.3389/fimmu.2021.692360] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Gonzalez-Pastor R, Goedegebuure PS, Curiel DT. Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer. Cancer Gene Ther 2021;28:375-89. [PMID: 32951021 DOI: 10.1038/s41417-020-00227-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Li X, Zeng S, Ding Y, Nie Y, Yang M. Comprehensive Analysis of the Potential Immune-Related Biomarker Transporter Associated With Antigen Processing 1 That Inhibits Metastasis and Invasion of Ovarian Cancer Cells. Front Mol Biosci 2021;8:763958. [PMID: 34957213 DOI: 10.3389/fmolb.2021.763958] [Reference Citation Analysis]
15 Ghoneum A, Almousa S, Warren B, Abdulfattah AY, Shu J, Abouelfadl H, Gonzalez D, Livingston C, Said N. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer. Semin Cancer Biol 2021:S1044-579X(21)00003-1. [PMID: 33476723 DOI: 10.1016/j.semcancer.2020.12.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Klemba A, Bodnar L, Was H, Brodaczewska KK, Wcislo G, Szczylik CA, Kieda C. Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies. Int J Mol Sci 2020;21:E9492. [PMID: 33327450 DOI: 10.3390/ijms21249492] [Reference Citation Analysis]
17 Zhang X, Wang Y, Deng H, Xiong X, Zhang H, Liang T, Li C. An aptamer biosensor for CA125 quantification in human serum based on upconversion luminescence resonance energy transfer. Microchemical Journal 2021;161:105761. [DOI: 10.1016/j.microc.2020.105761] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
18 Bronger H. Immunology and Immune Checkpoint Inhibition in Ovarian Cancer - Current Aspects. Geburtshilfe Frauenheilkd 2021;81:1128-44. [PMID: 34629492 DOI: 10.1055/a-1475-4335] [Reference Citation Analysis]
19 Chang CM, Li YF, Lin HC, Lu KH, Lin TW, Liu LC, Su KM, Chang CC. Dysregulated Immunological Functionome and Dysfunctional Metabolic Pathway Recognized for the Pathogenesis of Borderline Ovarian Tumors by Integrative Polygenic Analytics. Int J Mol Sci 2021;22:4105. [PMID: 33921111 DOI: 10.3390/ijms22084105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, Dever D, Stanbery L, Aaron P, Manning L, Walter A, Edelman G, Dworkin L, Nemunaitis J. Current Ovarian Cancer Maintenance Strategies and Promising New Developments. J Cancer 2021;12:38-53. [PMID: 33391401 DOI: 10.7150/jca.49406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
21 Maas RJ, Hoogstad-van Evert JS, Van der Meer JM, Mekers V, Rezaeifard S, Korman AJ, de Jonge PK, Cany J, Woestenenk R, Schaap NP, Massuger LF, Jansen JH, Hobo W, Dolstra H. TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. Oncoimmunology 2020;9:1843247. [PMID: 33224630 DOI: 10.1080/2162402X.2020.1843247] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
22 Lu W, Zhang F, Zhong X, Wei J, Xiao H, Tu R. Immune Subtypes Characterization Identifies Clinical Prognosis, Tumor Microenvironment Infiltration, and Immune Response in Ovarian Cancer. Front Mol Biosci 2022;9:801156. [DOI: 10.3389/fmolb.2022.801156] [Reference Citation Analysis]
23 Larionova I, Tuguzbaeva G, Ponomaryova A, Stakheyeva M, Cherdyntseva N, Pavlov V, Choinzonov E, Kzhyshkowska J. Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers. Front Oncol 2020;10:566511. [PMID: 33194645 DOI: 10.3389/fonc.2020.566511] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
24 Książek K. Molecular Biology of Ovarian Cancer: From Mechanisms of Intraperitoneal Metastasis to Therapeutic Opportunities. Cancers (Basel) 2021;13:1661. [PMID: 33916182 DOI: 10.3390/cancers13071661] [Reference Citation Analysis]
25 Gao P, Peng T, Cao C, Lin S, Wu P, Huang X, Wei J, Xi L, Yang Q, Wu P. Association of CLDN6 and CLDN10 With Immune Microenvironment in Ovarian Cancer: A Study of the Claudin Family. Front Genet 2021;12:595436. [PMID: 34249076 DOI: 10.3389/fgene.2021.595436] [Reference Citation Analysis]
26 Pereira M, Matuszewska K, Jamieson C, Petrik J. Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer. Front Endocrinol (Lausanne) 2021;12:772349. [PMID: 34867818 DOI: 10.3389/fendo.2021.772349] [Reference Citation Analysis]
27 Lang SM, Dorigo O. Cell-based immunotherapies in gynecologic cancers. Curr Opin Obstet Gynecol 2022;34:10-4. [PMID: 34967809 DOI: 10.1097/GCO.0000000000000760] [Reference Citation Analysis]